We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Senate Judiciary Committee members and generics makers Tuesday both sung the praises of a bill aimed at preventing branded drugmakers from restricting access to their products. Read More
The U.S. Supreme Court has asked the solicitor general to consider if a lower court erred in mandating that Novartis wait six months after approval of a biosimilar before going to market. Read More
The introduction of biosimilars to certain European countries has lowered drug prices by 50 percent to 60 percent in certain therapy areas, a report says. Read More
The UK’s drug pricing watchdog is recommending reimbursement of Bristol-Myers Squibb’s melanoma combination treatment of Opdivo and Yervoy, provided the company discounts the latter. Read More
The Justice Department was handed a surprise setback Friday when a jury acquitted Warner Chilcott’s former president of conspiring to pay kickbacks to physicians for prescribing seven of the company’s drugs. Read More
Despite appeals, the UK’s drug pricing watchdog has held firm against reimbursing Vertex Pharmaceuticals’ cystic fibrosis drug Orkambi, once again noting its modest short-term benefits to lung function and unknown long-term improvements. Read More